DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vatalanib
Vatalanib
Targeting Fibrosis in the Duchenne Muscular Dystrophy Mice Model: an Uphill Battle
From Celebrex to a Novel Class of Phosphoinositide-Dependent Kinase 1 (Pdk-1) Inhibitors for Androgen-Independent Prostate Caner
Tyrosine Kinase Inhibitor, Vatalanib, Inhibits Proliferation and Migration of Human Pterygial Fibroblasts
Prognostic and Predictive Role of Lactate Dehydrogenase 5 ( LDH5) Expression in Colorectal Cancer Patients Treated with PTK787/Z
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
(12) United States Patent (10) Patent No.: US 8,945,572 B2 Chant Et Al
Piperazine Are Toll-Like Receptor 4 Antagonists, Inhibit NF-Κb Activation, and Decrease TNF-Alpha Secretion in Primary Microglia
Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
Angiogenesis and Tumor Progression Inhibition of Cyclooxygenase-2 Selective Inhibitor Celecoxib Associated with Poly (Lactic-Co
Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) As First-Line Treatment of Metastatic Colorectal Cancer: the RESPECT Trial
(12) United States Patent (10) Patent No.: US 7,910,098 B2 Fuh Et Al
Cardio-Oncology: Basics and Knowing When You Need an Echo
The Role of Receptor Tyrosine Kinases in Mediating Glioblastoma Resistance to Radiotherapy and Temozolomide
Association of Mutations with All Drugs
Stembook 2018.Pdf
(12) Patent Application Publication (10) Pub. No.: US 2007/0259814 A1 Lynch (43) Pub
Vatalanib for Metastatic Gastrointestinal Stromal Tumour (GIST) Resistant to Imatinib: Final Results of a Phase II Study
FIGURE 1 Human Subjects with Bispecific Anti-CD 123 X Anti-CD3 Antibodies
Top View
VEGF Inhibitors in Brain Tumors
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
Angiogenic Influences on Hematopoietic Cells In
Antiproliferative and Carbonic Anhydrase II Inhibitory
Theranostics Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance Against Angiogenesis Inhibitors
The Potential of Antiangiogenictherapy in Non ^ Small Cell Lung Cancer Giuseppe Giaccone
New Perspectives in the Treatment of Neuroendocrine Tumours
(12) Patent Application Publication (10) Pub. N0.: US 2014/0235631 A1 Bunt Et Al
A Phase I Study of the Vascular Endothelial Growth Factor Inhibitor Vatalanib in Combination with Pemetrexed Disodium in Patients with Advanced Solid Tumors
Role of VEGF/VEGFR in the Pathogenesis of Leukemias and As Treatment Targets (Review)
Refinement of in Vitro Methods for Identification of Aldehyde Oxidase Substrates Reveals Metabolites of Kinase Inhibitors
Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations Adam A
WO 2014/152330 Al 25 September 2014 (25.09.2014) P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Alternative Vascularization Mechanisms in Tumor Resistance to Therapy
Customs Tariff - Schedule Xxi - 1
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase
VEGF Targeted Therapy in Acute Myeloid Leukemia
WO 2Ull/1563Ol A2
Current Treatment Options for Meningioma Caroline Apra, Matthieu Peyre, Michel Kalamarides
WO 2018/223002 Al 06 December 2018 (06.12.2018) W ! P O PCT
Extracting Biological Knowledge from High Throughput
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/Mtor, Aurora Kinase and EZH2 Inhibitors
Small Molecule Inhibitors in Pancreatic Cancer
Different Regulation of Physiological and Tumor Angiogenesis in Zebrafish by Protein Kinase D1 (PKD1)
Compositions for Treating Breast Cancer
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tu M O U R S
Tyrosine Kinase Inhibitors Enhanced the Efficacy of Conventional Chemotherapeutic Agent in Multidrug Resistant Cancer Cells Shaocong Wu and Liwu Fu*
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Jamesj
Vatalanib for Metastatic Gastrointestinal Stromal Tumour (GIST) Resistant to Imatinib: Final Results of a Phase II Study
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy
Bone Marrow Niche Dysregulation in Myeloproliferative Neoplasms Ferrata Storti Foundation
Vascular Density Analysis in Colorectal Cancer Patients Treated with Vatalanib (PTK787/ZK222584) in the Randomised CONFIRM Trials
Cell-Centric View of Apoptosis and Apoptotic Cell Death-Inducing Antitumoral Strategies
Learningpharmacology 2018.Pdf
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
Haematol.2018.214882.Full